Status:
COMPLETED
Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder
Lead Sponsor:
Osaka City University
Conditions:
SSRI-Refractory Obsessive-Compulsive Disorder
Eligibility:
All Genders
20-50 years
Phase:
PHASE4
Brief Summary
Objective: Although atypical antipsychotic drugs (AAPDs) have been found effective in the augmentation of serotonin reuptake inhibitors (SRIs) for treatment-resistant obsessive-compulsive disorder (OC...
Detailed Description
More recently, second-generation atypical antipsychotic drugs (AAPD) that modulate both 5-HT and DA function, such as risperidone (RIS), olanzapine (OLZ) and quetiapine (QET), have been found effectiv...
Eligibility Criteria
Inclusion
- Male or female, 18 years of age or over
- Patients were diagnosed as having obsessive-compulsive disorder by the Structured Clinical Interview for DSM-IV Patient version (SCID-P)
- They received standardized treatment for at least 1 year at the OCD clinic in our university hospital.
- Each subject gave written informed consent to take part after receiving a complete description of this study.
- All subjects were free of medical illness based on results of physical examination and screening tests of blood and urine, and no subjects received any lipid lowering or hypoglycemic agent during the 1-year study period.
Exclusion
- Current clinically significant medical conditions such as diabetes
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
December 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00854919
Start Date
January 1 2006
End Date
December 1 2007
Last Update
March 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept of Neuropsychiatry, Osaka City University, graduate School of Medicine
Osaka, Osaka, Japan, 545-8585